Cargando…
TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients
Telomerase reverse transcriptase gene promoter (TERTp) mutations are recognized as one of the most frequent genetic events in bladder cancer (BC). No studies have focused on the relevance of TERTp mutations in the specific group of tumors treated with Bacillus Calmette–Guérin (BCG) intravesical ther...
Autores principales: | Batista, Rui, Lima, Luís, Vinagre, João, Pinto, Vasco, Lyra, Joana, Máximo, Valdemar, Santos, Lúcio, Soares, Paula |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037401/ https://www.ncbi.nlm.nih.gov/pubmed/32023888 http://dx.doi.org/10.3390/ijms21030947 |
Ejemplares similares
-
Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review
por: Batista, Rui, et al.
Publicado: (2020) -
TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes
por: Vinagre, João, et al.
Publicado: (2016) -
TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas
por: Melo, Miguel, et al.
Publicado: (2014) -
Clinical Validation of a Urine Test (Uromonitor-V2(®)) for the Surveillance of Non-Muscle-Invasive Bladder Cancer Patients
por: Sieverink, Caroline A., et al.
Publicado: (2020) -
Genetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas
por: Soares, Paula, et al.
Publicado: (2011)